ArticleNature medicine2023
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Open access · bronzeAbstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases.Annals of medicine · 2026Review
- Chimeric antigen receptor T-cell therapy for rheumatic diseases: from B-cell depletion to immune reset and beyond.Frontiers in immunology · 2026Review
- Foundational Principles for the Quantitative Translation of T-Cell Therapeutics for Hematologic Malignancies and Immunology.Clinical pharmacology and therapeutics · 2026Review
- Therapeutic progress in the targeting of B cells in lupus nephritis: pathogenesis to clinical research.International urology and nephrology · 2025Review
- Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis.Frontiers in immunology · 2025Review
- A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.International journal of molecular sciences · 2024Review
- CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.Frontiers in immunology · 2024Review
- CAR T cells induce drug-free SLE remission.Nature reviews. Rheumatology · 2022Article
- Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis.Nature reviews. Rheumatology · 2022Review
Corrections and comments
- Erratum for
Authors and funding
24 authors at 2 institutions in 1 country.
Andreas Mackensen *Department of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0685-4483
Fabian Müller *Department of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Dimitrios Mougiakakos *Department of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Sebastian BöltzDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-5227-8707
Artur WilhelmDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-4637-1582
Michael AignerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Simon VölklDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
David SimonDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-8310-7820
Arnd KleyerDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-2026-7728
Luis MunozDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Sascha KretschmannDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Soraya KharboutliDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Regina GaryDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Hannah ReimannDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-7336-2008
Wolf RöslerDepartment of Internal Medicine 5-Hematology and Oncology, Friedrich Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
Stefan UderhardtDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Holger BangOrgentec, Mainz, Germany.
Martin HerrmannDeutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0258-2484
Arif Bülent EkiciInstitute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-6099-7066
Christian BuettnerInstitute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Katharina Marie HabenichtDivision of Genetics, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Thomas H WinklerDivision of Genetics, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-1860-0528
Gerhard Krönke *Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0002-7566-4325
Georg Schett *Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. georg.schett@uk-erlangen.de.ORCID http://orcid.org/0000-0001-8740-9615
Universitätsklinikum Erlangen · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.